GENINUS Inc.
Research GENINUS Inc. (389030.KQ) on Bullrun: market cap KRW 65.00B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker389030.KQ
- ExchangeKQ
- CountrySouth Korea
- SectorHealthcare
- IndustryBiotechnology
- CurrencyKRW
- Market capKRW 65.00B
- Financial periodQ2 2026
- RevenueKRW 3.61B
- Net income-KRW 7.75B
- Free cash flow-KRW 1.23B
- Gross margin-2.4%
Valuation Snapshot
latest market cap is KRW 65.00B.
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | KRW 65.00B | n/a | n/a | n/a |
Dividend history
About GENINUS Inc.
GENINUS Inc., a bioinformation analysis company, engages in the research and development, manufacture, and sale of genome analysis solutions in South Korea, the United States, and Asia. It offers tarhet and biomarker discovery; AI digital pathology; single cell analysis; and spatial and in-situ transcriptomics services; and SPACEINSIGHT, a cutting-edge cloud based integrated analysis platform. It serves hospitals, pharmaceutical companies, and researchers.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is GENINUS Inc.'s market cap?
GENINUS Inc.'s market capitalization is KRW 65.00B.
What does GENINUS Inc. do?
GENINUS Inc., a bioinformation analysis company, engages in the research and development, manufacture, and sale of genome analysis solutions in South Korea, the United States, and Asia. It offers tarhet and biomarker discovery; AI digital pathology; single cell analysis; and spatial and in-situ transcriptomics services; and SPACEINSIGHT, a cutting-edge cloud based integrated analysis platform. It serves hospitals, pharmaceutical companies, and researchers. The company was founded in 2018 and is headquartered in Seoul, South Korea.